Table 2. NOACs versus Warfarin for stroke prevention in patients with atrial fibrillation.

NOAC	Primary Efficacy endpoint vs. Warfarin RR [95% CI]		Primary Safety endpoint * vs. Warfarin RR [95% CI]
	General population **	Cancer ***	General population **	Cancer ***
Dabigatran	0.91 [0.53-0.82] †	0.14 [0.03 - 0.57] §	0.93 [0.81-1.07] †	0.23 [0.07-0.74] §
Rivaroxaban	0.79 [0.66-0.96]	0.52 [0.22-1.21]	1.03 [0.96-1.11]	1.09 [0.82-1.44] ††
Apixaban	0.79 [0.66-0.95]	1.09 [0.56-2.26]	0.69 [0.60-0.80]	0.80 [0.56-1.14] ††
Edoxaban	0.79 [0.63-0.99] ‡	0.60 [0.31-1.15] ‡	0.87 [0.73-1.04] ‡	0.98 [0.69–1.40] ‡

^*Major bleeding results, unless otherwise specified.

^**Data from landmark RCTs.

^***Data from post-hoc subanalysis or observational studies.

^§Results from an observational retrospective study, which included 140 patients on Dabigatran, and counted two ischemic strokes and three major bleeding events in this study arm (Kim K, et al. 2018].

^†The results for Dabigatran 150mg dosage are presented.

^††Major or clinically relevant nonmajor bleeding events.

^‡The results for Edoxaban 60mg dosage are presented.